patients' stones, which all contained more than 70% cholesterol, 10 contained at least 1 % calcium on the stone surface. In two patients, the surface contained sufficient calcium to form a radioopaque layer, although the stones had been radiolucent at the start of dissolution therapy. Overall, the results suggest that deposition of calcium salts inhibits the dissolution treatment of gallstones with chenodeoxycholic acid, irrespective of the radiolucency of the stones.
Several clinical trials of the efficacy of chenodeoxycholic acid (CDCA) in dissolving radiolucent gallstones in functioning gallbladders have indicated that stones decrease in size during treatment in about one-half of patients, while in only one-third of patients do stones completely- '- Gallstones were removed from the gallbladder, washed free of bile with methanol and distilled water, and dried. After weighing, a thin (<1 mm) surface layer was sectioned from the stones from each patient and a sample from the stone centre was also taken for cholesterol and calcium determination. Total stone cholesterol and calcium was determined after grinding several stones, or half a stone when only one was present, to a fine powder with a mortar and pestle.
Gallstones were also obtained from 89 consecutive patients (24 men and 65 women; age range 20 to 74 years) presenting for cholecystectomy with radiolucent cholesterol stones in a functioning gallbladder. These patients were not treated with CDCA, and their stones were analysed for total cholesterol and calcium, and for surface and interior calcium in a random sample of 20 stones.
CHEMICAL ANALYSIS OF GALLSTONES
Cholesterol Samples of gallstone powder (approximately 50 mg) were dried at 60°C overnight to achieve constant weight, and were then extracted twice with 4 ml isopropanol at 600 for one hour. The isopropanol extracts w-ere combined, made up to 10 ml final volume, and cholesterol was estimated by gas-liquid chomatography, using cholesterol isopropyl ether as internal standard. The column (1 .2 m x 2 mm i.d.) used for cholesterol determination was packed with 3 % SP-2250 on Supelcoport 100-120 mesh (Supelco, Inc., Bellafonte, Penn., USA) and used at 2650 with nitrogen (30 ml/min) as carrier gas.
Calcium
The residue remaining after solvent extraction was treated with 2 ml of 1 M nitric acid, centrifuged and the supernatant collected. Concentrated nitric acid (0.2 ml) was added to the residue, followed by 1 ml of water, and the centrifugation was repeated. After washing the pellet with water, the combined supernatants were made up to 10 ml with water, and calcium estimated on a Varian Techtron AA6 atomic absorption spectrophotometer.
ANALYSIS OF BILIARY LIPIDS
Bile collected by duodenal intubation was analysed for cholesterol, bile acids, and phospholipid as follows. Within one hour of collection, duplicate 50 ,ul aliquots of bile were mixed with 50 ,ul cholesterol isopropyl ether (5 mM) as internal standard and then subjected to solvent extraction by the Folch procedure.10 Aliquots of the lower phase were taken and evaporated to dryness for phospholipid estimation" and for cholesterol determination by gas-liquid chromatography, using the same conditions as described for gallstone cholesterol estimation. Total bile acids were determined enzymatically'2 after dilution of bile with 70 % (v/v) methanol.
The cholesterol saturation index was calculated by the method of Thomas and Hofmann'3 using the cholesterol equilibrium saturation limit of Holzbach et al. '4 STATISTICS The statistical test used was the non-parametric Mann-Whitney U test.
Results

COMPLIANCE WITH CDCA TREATMENT
During dissolution treatment with CDCA, compliance was assessed in six patients by bile lipid analysis. The biliary cholesterol saturation index was reduced after three months CDCA treatment from 1P19+0.28 to 0'80]0.24 (mean +SD) with all bile sari'pres analysed except one becoming unsaturated with respect to cholesterol. The percentage CDCA in bile changed from 41+9 to 88±6%4. In another five patients, compliance was assessed by serum bile acid analysis'5 and the predicted percent CDCA in bile changed after treatment from 49 ± 7 % to 83 +4%.
DESCRIPTION OF GALLSTONES RESISTANT TO DISSOLUTION TREATMENT
Details of patients and the properties of their gallstones which were resistant to dissolution treatment are shown in Table 1 . Many of the patients were obese, as determined by their body mass index (weight in kg/(height in m)2), for which the normal range is 20-25.16 The average time of treatment with CDCA was 10 months, with all patients receiving at least six months' treatment. There was a wide variation in the number of stones found in each patient's gallbladder, ranging from a single stone to approximately 200 small stones. Half the patients had rounded stones, which were usually solitary while the rest were multiple and faceted. The range of stone sizes present in each patient frequently included stones with a diameter over 10 mm and the total mass of stones varied from 0.3 to 34-3 g.
Three patients' stones were black in colour (nos. 6, 7, and 14) suggesting that they were pigment stones. Chemical analysis confirmed that two of these stones (nos. 6 and 7) were low in cholesterol content compared with the others, all of which contained at least 70 % cholesterol. The black stones Table 1 ).
The interiors and surface layers of stones collected from 20 patients sampled randomly from the 89 patients not treated with CDCA were then analysed to determine the distribution of calcium throughout the stones. In 13 of these stones, the surface contained a higher concentration of calcium than the interior, while, in six stones, the reverse was true. In one patient's stones, there was no difference between the surface and the interior of the stone. The median ratio of surface to interior calcium content in this group was 2.4, which was significantly lower (p <0.01) than the value of 7.8 for the stones which were unaffected by dissolution treatment. One of these factors is the dosage of CDCA, which must be adequate to produce unsaturated bile in all patients. It has been accepted by most groups that 15 mg/kg/day is the optimum dose.4 Other factors are patient compliance and the length of treatment. At least six months are required to allow the slow process of dissolution to occur.4 In addition, the gallbladder should have good function-that is, opacify well during cholecystography and contract promptly in response to a meal, so that stones are continually exposed to unsaturated bile secreted by the liver. There is also some evidence that grossly obese patients will not respond to CDCA treatment4 because excessive cholesterol secretion prevents the bile from becoming unsaturated. '8 The 14 patients reported in this study were all treated with CDCA at 15 mg/kg/day for at least six months, complied with treatment in the 11 cases examined, and had functioning gallbladders. While many of the patients were obese (median body mass index 28-0; range 21 1-37.6), they were not significantly more obese than a group of 10 patients (median body mass index 26.3, range 18.3-32 7) whose stones were completely dissolved after CDCA treatment (unpublished results A feature of the remaining 12 patients' stones, which all contained 70% or more cholesterol, was the higher calcium content compared with radiolucent cholesterol stones collected from patients not treated with CDCA. In addition, there was a markedly uneven distribution of calcium between the surface and the interior of the stones, with 11 of the patients having a greater calcium concentration on the surface. In fact, in two patients, the calcium layer in the stone surface reached sufficient concentration to become radio-opaque, although the stones were lucent at the start of CDCA therapy. As eight other patients had surface calcium levels which were over 1 %, it is possible that a layer of calcium salt, probably calcium carbonate in most cases, formed a barrier between the cholesterol in the stone and the solubilising bile in the gallbladder. Almost all gallstones contain some calcium salts and these are rarely distributed uniformly throughout the stone but are concentrated in layers, often on the stone surface. A layer on the outside of the stone could completely prevent dissolution, while a layer within the stone could allow partial dissolution of the stone until the layer is reached. The presence of calcium carbonate on the surface of gallstones has been described previously and may be associated with a raised total CO2 concentration in common bile duct bile21 rather than a change in biliary calcium concentration.22
Other factors, such as stone size and number of stones, are likely to affect the rate of dissolution, and treatment periods in excess of 12 months may be required to effect a detectable reduction in gallstone size in some patients. However, it appears from these results that the presence of calcium carbonate in gallstones inhibits dissolution, even though the amount and distribution of calcium within the stone may not result in it being radio opaque. Gallstones from patients over 50 years old contain significantly more calcium than stones from patients less than 501' and this finding is consistent with the deposition of calcium salts on the surface of old (>six years) gallstones, as suggested by Wolpers.23 CDCA therapy should therefore be most effective in young patients with cholesterol gallstones which are recent in origin and contain low levels of calcium salts. 
